303 related articles for article (PubMed ID: 23147191)
1. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
8. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
13. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
17. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
18. [Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Duan JC; Wu MN; Zhao J; An TT; Yang L; Bai H; Wang ZJ; Zhuo ML; Wang SH; Wang YY; Liu XH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):97-101. PubMed ID: 22455964
[TBL] [Abstract][Full Text] [Related]
19. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
